Cargando…

Is DAA Treatment Associated with HBV Reactivation? Results from ERCHIVES

BACKGROUND: Reactivation of HBV infection has been reported in patients with HCV treated with newer directly acting antiviral agents (DAAs). Magnitude of this problem and its consequences are not fully understood. METHODS: Using ERCHIVES, a well-established national database of HCV infected Veterans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butt, Adeel, Yan, Peng, Shaikh, Obaid, Abou-Samra, Abdul-Badi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631867/ http://dx.doi.org/10.1093/ofid/ofx163.382

Ejemplares similares

930. HCV Treatment Is Associated With a Reduced Risk of Cardiovascular Disease Events: Results From ERCHIVES
por: Butt, Adeel Ajwad, et al.
Publicado: (2018)

HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

The Incidence of Hepatocellular Carcinoma Is not Increased in Individuals with Chronic Hepatitis C After Treatment with Interferon-free Regimens: an ERCHIVES Study
por: Li, Darrick K, et al.
Publicado: (2017)

Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir/Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES
por: Butt, Adeel, et al.
Publicado: (2017)

Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES
por: Butt, Adeel A., et al.
Publicado: (2015)

285. Fibrosis Progression and Clinical Outcomes in HCV/HBV Coinfected Persons in the ERCHIVES Cohort
por: Butt, Adeel A, et al.
Publicado: (2019)

2219. Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study
por: Butt, Adeel Ajwad, et al.
Publicado: (2018)

2896. Reduction in Liver-related Mortality Among HCV Infected Persons Is Driven by Attainment of SVR Independent of the Regimen Used: Results from the ERCHIVES Cohort
por: Butt, Adeel A, et al.
Publicado: (2019)

Fibrosis Progression and Incidence of Cirrhosis and Hepatic Decompensation in Persons Treated with Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir: Results from ERCHIVES
por: Simon, Tracey, et al.
Publicado: (2017)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
por: Tayyab, Ghias Un Nabi, et al.
Publicado: (2020)

294. Hepatitis C Virologic Response in Hepatitis B and C Coinfected Persons Treated with Directly Acting Antiviral Agents: Results from ERCHIVES
por: Butt, Adeel A, et al.
Publicado: (2019)

514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression
por: Butt, Adeel A, et al.
Publicado: (2023)

304. Hepatocellular Carcinoma Occurs Frequently and Early After Treatment in HCV Genotype 3 Infected Persons Treated with DAA Regimens
por: Un Nabi Tayyab, Ghias, et al.
Publicado: (2019)

Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use
por: Butt, Adeel A., et al.
Publicado: (2021)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019)

Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study
por: Mücke, Marcus M, et al.
Publicado: (2018)

292. No association Between Direct-acting Antiviral (DAA) Therapy and Varicella-Zoster Virus (VSV) Reactivation in an Analysis of 37 Prospective Clinical Trials
por: Rohde, Maximilian, et al.
Publicado: (2019)

Impact of COVID-19 upon changes in emergency room visits with chest pain of possible cardiac origin
por: Butt, Adeel A., et al.
Publicado: (2020)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

2273. Azithromycin Use Before and During COVID- 19 and Impact of Implementing Evidence-based Guidelines
por: Shams, Sherin, et al.
Publicado: (2023)

2491. The Association of Parkinson’s Disease with Hepatitis C Virus Infection and Its Treatment
por: Aslam, Samia, et al.
Publicado: (2023)

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
por: Colombatto, Piero, et al.
Publicado: (2022)

Volume and Acuity of Emergency Department Visits Prior To and After COVID-19
por: Butt, Adeel A., et al.
Publicado: (2020)

Steps and Challenges in Creating and Managing Quarantine Capacity During a Global Emergency – Qatar’s Experience
por: Masoodi, Naseer, et al.
Publicado: (2021)

COT-06 HBV REACTIVATION DURING AND AFTER THE TREATMENT OF MALIGNANT GLIOMA WITH TEMOZOLOMIDE
por: Kanamori, Masayuki, et al.
Publicado: (2019)

COVID-19 infection among healthcare workers in a national healthcare system: The Qatar experience
por: Alajmi, Jameela, et al.
Publicado: (2020)

SARS-CoV-2 Polymerase Chain Reaction Positivity Rates Among Evacuees From Afghanistan After Withdrawal of the Coalition Forces
por: Butt, Adeel A., et al.
Publicado: (2022)

Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population
por: Butt, Adeel A., et al.
Publicado: (2021)

Telehealth for Hepatitis C Care in the DAA Era; Ensuring Everyone Can Access a Cure
por: Schulz, Thomas Ray, et al.
Publicado: (2017)

The Impact of Hepatitis C Virus (HCV) Treatment with Direct-Acting (DAA) on the Incidence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Liver Disease
por: De Comarmond, Charles, et al.
Publicado: (2017)

DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b
por: De Francesco, Maria Antonia, et al.
Publicado: (2022)

Retreatment of Chronic HCV Infection after Second Generation DAA Failure in Patients in the NJ VA Healthcare System
por: Stawarz, Kimberly, et al.
Publicado: (2017)

Significant early and long-term improvement of neuropsychiatry symptomatology in HCV-infected patients after viral eradication with DAA
por: Martin-Santos, R., et al.
Publicado: (2022)

Management Of Patients With Hepatitis B Virus Reactivation Post–DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV–HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis
por: Osman, Heba Ahmed, et al.
Publicado: (2019)

Treatment of hepatitis C in HIV patients in the new DAA era
por: Soriano, Vicente
Publicado: (2014)

Treatment of hepatitis C virus genotype 4 in the DAA era
por: Di Biagio, Antonio, et al.
Publicado: (2018)

Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination
por: Butt, Adeel A., et al.
Publicado: (2021)

310. Disparities in Hepatitis C Linkage to Care in the DAA Era: Findings from a Referral Clinic with an Embedded Nurse Navigator Model
por: Sherbuk, Jacqueline, et al.
Publicado: (2019)

Seroprevalence of SARS-CoV-2 Infection Among Working Women and Impact of Workplace Restrictions
por: Alishaq, Moza, et al.
Publicado: (2022)

SARS-CoV-2 PCR and antibody positivity among school staff at the beginning and end of the first school term
por: Alishaq, Moza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_alfmrjpuhcu64do2cp14gl024g